Other News To Note
Friday, September 27, 2013
• Agenus Inc., of Lexington, Mass., entered a nonexclusive license agreement with Vaxlogic LLC, a subsidiary of Boca-Raton, Fla.-based Pharmlogic LLC, for the use of QS-21 Stimulon adjuvant in the development of select addiction, allergy and respiratory disease vaccine candidates.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.